Medistim Asa · OSL:MEDI

Medistim Asa — Q4 2018 Earnings Presentation

26 slides from Medistim Asa's earnings presentation, Feb 27, 2019

  1. Slide 1: Medistim ASA Fourth quarter 2018

    Medistim ASA Fourth quarter 2018 Kari E. Krogstad, President and CEO Thomas Jakobsen, CFO February 27th, 2019

  2. Slide 2: Disclaimer

    2 27.02.2019 Medistim ASA Q4 2018 Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Medistim ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These s

  3. Slide 3: Table of contents

    3 27.02.2019 Medistim ASA Q4 2018 Table of contents 1. Highlights fourth quarter 2. Financial statements 3. Business segments update 4. Implementing the strategy

  4. Slide 4: 1. Highlights 4th quarter

    MED (STIM 1. Highlights 4th quarter

  5. Slide 5: Highlights 4th quarter 2018

    5 27.02.2019 Medistim ASA Q4 2018 Highlights 4th quarter 2018 Q4 2018 QoQ • Sales for the fourth quarter 2018 is the best ever for Revenue 19.1% Medistim with a 19.1 % growth over Q4 2017, which was MNOK 97.9 (82.2) the previous all time high quarter o Currency neutral sales of own products up 25.5

  6. Slide 6: Medistim ASA Q4 2018

    6 27.02.2019 Medistim ASA Q4 2018

  7. Slide 7: 2. Financial statements

    2. Financial statements

  8. Slide 8: Profit and loss Q4 2018

    8 27.02.2019 Medistim ASA Q4 2018 Profit and loss Q4 2018 Sales per Quarter (TNOK) Profit & loss Q4 2018 Q4 2017 All numb ers in NOK 1000 110 000 100 000 Sales 97 923 82 230 90 000 Cost of goods sold 20 999 20 576 80 000 70 000 Salary and sosial expenses 30 791 26 720 60 000 Other operating expenses

  9. Slide 9: Profit and loss 2018

    9 27.02.2019 Medistim ASA Q4 2018 Profit and loss 2018 Profit & loss 2018 2017 Sales per Quarter (TNOK) All numb ers in NOK 1000 110 000 Sales 325 890 301 461 100 000 90 000 Cost of goods sold 79 381 72 782 80 000 Salary and sosial expenses 105 314 98 281 70 000 Other operating expenses 54 857 51 70

  10. Slide 10: Balance sheet - Assets

    10 27.02.2019 Medistim ASA Q4 2018 Balance sheet - Assets Balance sheet 31.12.2018 31.12.2017 300 000 All numb ers in NOK 1000 250 000 Assets 200 000 Intangible assets 41 944 45 090 150 000 Fixed assets 37 198 25 744 Total intangible and fixed assets 79 142 70 834 100 000 Inventory 63 843 62 722 50

  11. Slide 11: Balance sheet - Equity and liability

    11 27.02.2019 Medistim ASA Q4 2018 Balance sheet - Equity and liability 300 000 Balance sheet 31.12.2018 31.12.2017 All numb ers in NOK 1000 250 000 Share capital 4 585 4 585 200 000 Premium fund 44 172 44 172 Other equity 157 955 134 226 150 000 Total equity 206 712 182 983 100 000 Total long term

  12. Slide 12: Medistim ASA Q4 2018

    12 27.02.2019 Medistim ASA Q4 2018

  13. Slide 13: 3. Business segments update

    3. Business segments update

  14. Slide 14: Flow probes and systems in units

    14 27.02.2019 Medistim ASA Q4 2018 Flow probes and systems in units Flow probes in units (excl USA) Flow systems in units (VeriQ & MiraQ capital sales) 2 500 40 35 2 000 30 1 500 25 Europe 20 US 1 000 15 ROW 500 10 Asia 5 - - Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 16 17 17 17 17 18

  15. Slide 15: Imaging probes and systems in units

    15 27.02.2019 Medistim ASA Q4 2018 Imaging probes and systems in units Imaging probes in units (incl USA) Imaging systems in units (VeriQC & MiraQ capital sales) 50 40 40 35 30 30 25 ROW 20 20 Europe 10 15 Asia - 10 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 US 5 16 17 17 17 17 18 18 18 18 0 Imaging probes US imagi

  16. Slide 16: Q4 and YTD revenue performance by region

    16 27.02.2019 Medistim ASA Q4 2018 Q4 and YTD revenue performance by region Mill NOK Q4 '18 Q4 '17 Q/Q 2018 2017 Y/Y Europe 38,8 40,0 -3,2 % 154,8 150,3 3,0 % USA 38,8 27,5 41,0 % 113,1 104,6 8,2 % Asia & Jp 13,8 5,7 143,7 % 38,7 27,0 43,4 % ROW 6,5 9,0 -27,5 % 19,3 19,6 -1,7 % (MEA, CAN, SA, AUS) T

  17. Slide 17: Q4 and YTD revenue performance by product

    17 27.02.2019 Medistim ASA Q4 2018 Q4 and YTD revenue performance by product Mill NOK Q4 '18 Q4 '17 Q/Q 2018 2017 Y/Y Procedures (USA) 27,5 21,6 27,3 % 89,5 86,0 4,0 % Flow probes 25,0 22,9 8,9 % 85,7 78,9 8,7 % Flow systems (VeriQ & MiraQ) 7,8 9,4 -17,7 % 32,5 23,3 39,3 % Imaging systems (VeriQ C &

  18. Slide 18: Medistim ASA Q4 2018

    18 27.02.2019 Medistim ASA Q4 2018

  19. Slide 19: 4. Implementing the strategy

    4. Implementing the strategy

  20. Slide 20: Growth opportunities – in developing Medistim markets

    20 27.02.2019 Medistim ASA Q4 2018 Growth opportunities – in developing Medistim markets 1. Convert the routine Flow market to a Flow-and- Imaging market by establishing Surgical Guidance and Quality Assessment as the new standard of care through Emerging, high-growth o Early adopter & KOL support e

  21. Slide 21: Performance US sales organization

    21 27.02.2019 Medistim ASA Q4 2018 60000 55000 Performance US sales organization 50000 45000 40000 35000 30000 25000 20000 RESULTS 2018 2010 2011 2012 2013 2014 2015 2016 2017 2018 Number of procedures per year • Revenues up 10 % in USD o Revenues up 8.2 % in NOK, to MNOK 113.1, 17 500 due to unfavo

  22. Slide 22: Growth opportunities – in developed Medistim markets

    22 27.02.2019 Medistim ASA Q4 2018 Growth opportunities – in developed Medistim markets 1. Convert the routine Flow market to a Flow-and- Imaging market by establishing Surgical Guidance and Quality Assessment as the new standard of care through Emerging, high-growth o Early adopter & KOL support ec

  23. Slide 23: REQUEST

    REQUEST Clinical Study 2018 EACTS ____________ Prof. DP Taggart Oxford University ….. Prof. G Di Giammarco University of Chieti ….. Dr. J Puskas Mount Sinai St Luke’s ….. Dr. D Wendt University of Essen ….. Dr. G Trachiotis George Washington University ….. Dr. T Kieser University of Calgary ….. Prof

  24. Slide 24: Final results from the REQUEST study

    Final results from the REQUEST study Surgical Quality In-hospital Guidance Assessment outcome HFUS of aorta, conduits TTFM & HFUS of MACCE 1,9% & coronary targets: anastomosis: Mortality 0,6% Change of surgical Revision rate 3% strategy in 25 % of Stroke 0,9% patients In the hands of experienced car

  25. Slide 25: 20 largest shareholders (per February 25th 2019)

    25 27.02.2019 Medistim ASA Q4 2018 20 largest shareholders (per February 25th 2019) Shareholder Number of shares Shares in % INTERTRADE SHIPPING AS 4 003 500 21,83 % SALVESEN & THAMS INVEST AS 1 862 500 10,16 % SWEDBANK ROBUR SMABOLAGSFOND 1 375 246 7,50 % Skandinaviska Enskilda Banken AB 1 041 753

  26. Slide 26: Seeing is believing

    26 27.02.2019 Medistim ASA Q4 2018 Seeing is believing

Medistim — Q4 2018 Earnings Presentation on 6ix